首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >Risk stratification in patients with unstable angina and/or non-ST-elevation myocardial infarction by Troponin T and plasminogen-activator-inhibitor-1 (PAI-1).
【24h】

Risk stratification in patients with unstable angina and/or non-ST-elevation myocardial infarction by Troponin T and plasminogen-activator-inhibitor-1 (PAI-1).

机译:肌钙蛋白T和纤溶酶原激活物抑制剂1(PAI-1)对不稳定型心绞痛和/或非ST抬高型心肌梗死的患者进行危险分层。

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Increased Troponin T (TnT) and PAI-1 levels are markers of poor outcome in acute coronary syndromes (ACS). In order to stratify the risk for 30-day combined endpoint of mortality and/or reinfarction in unstable angina and/or non-ST-elevation myocardial infarction (UA/NSTEMI), TnT and PAI-1 levels were simultaneously assessed. Methods: The TnT and PAI-1 levels of 113 patients with UA/NSTEM were estimated within the first 48 h. Initial therapy was medical. Percutaneous coronary interventions were performed in case of recurrent ischemia and/or hemodynamic and/or rhythmic instability. Results: Statistically significant differences in mean admission PAI-1 (4.2+/-3.4 vs. 2.8+/-2.4 U/ml, p<0.05), mean peak PAI-1 levels within the first 48 h (4.98+/-3.1 vs. 3.4+/-2.5 U/ml, p<0.05), and no significant difference in any TnT level were observed between patients with and without 30-day mortality and/or reinfarction. The risk for 30-day mortality and/or reinfarction significantly increased in patients with admission PAI-1 levels > 4.0 U/ml (OR=4.44, 95%CI=1.47-13.4), peak PAI-1 levels>4.0 U/ml (OR=5.78, 95%CI=1.838-18.20) and with simultaneously increased peak PAI-1 > 3.5 U/ml and TnT > 0.1 microg/l within the first 48 h (OR=4.9, 95%CI=1.569-15.385). Conclusions: Simultaneous assessment of TnT and PAI-1 would provide complementary prognostic information and enable clinicians to stratify risk more effectively among patients with UA/NSTEMI.
机译:背景:肌钙蛋白T(TnT)和PAI-1水平升高是急性冠脉综合征(ACS)预后不良的标志。为了对不稳定型心绞痛和/或非ST段抬高型心肌梗死(UA / NSTEMI)的死亡和/或再梗塞的30天联合终点风险进行分层,同时评估了TnT和PAI-1水平。方法:在开始的48小时内评估了113例UA / NSTEM患者的TnT和PAI-1水平。最初的治疗是药物治疗。在反复缺血和/或血液动力学和/或节律性不稳定的情况下,进行经皮冠状动脉介入治疗。结果:平均入院PAI-1(4.2 +/- 3.4与2.8 +/- 2.4 U / ml,p <0.05),前48小时内平均峰值PAI-1水平(4.98 +/- 3.1)具有统计学意义的差异vs. 3.4 +/- 2.5 U / ml,p <0.05),在有和没有30天死亡率和/或再梗死的患者之间,任何TnT水平均未观察到显着差异。入院PAI-1水平> 4.0 U / ml(OR = 4.44,95%CI = 1.47-13.4),峰值PAI-1水平> 4.0 U / ml的患者30天死亡和/或再梗塞的风险显着增加(OR = 5.78,95%CI = 1.838-18.20)并且在前48小时内峰值PAI-1> 3.5 U / ml和TnT> 0.1 microg / l同时增加(OR = 4.9,95%CI = 1.569-15.385 )。结论:同时评估TnT和PAI-1可提供补充的预后信息,并使临床医生能够更有效地对UA / NSTEMI患者进行风险分层。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号